Drugs,
Journal Year:
2022,
Volume and Issue:
82(3), P. 251 - 274
Published: Feb. 1, 2022
Alcohol
use
disorder
(AUD)
is
a
highly
prevalent
but
severely
under-treated
disorder,
with
only
three
widely-approved
pharmacotherapies.
Given
that
AUD
very
heterogeneous
it
unlikely
one
single
medication
will
be
effective
for
all
individuals
an
AUD.
As
such,
there
need
to
develop
new,
more
effective,
and
diverse
pharmacological
treatment
options
the
hopes
of
increasing
utilization
improving
care.
In
this
qualitative
literature
review,
we
discuss
efficacy,
mechanism
action,
tolerability
approved,
repurposed,
novel
pharmacotherapies
clinical
perspective.
Pharmacotherapies
discussed
include:
disulfiram,
acamprosate,
naltrexone,
nalmefene,
topiramate,
gabapentin,
varenicline,
baclofen,
sodium
oxybate,
aripiprazole,
ondansetron,
mifepristone,
ibudilast,
suvorexant,
prazosin,
doxazosin,
N-acetylcysteine,
GET73,
ASP8062,
ABT-436,
PF-5190457,
cannabidiol.
Overall,
many
repurposed
agents
in
review
demonstrate
effectiveness
promise
future
treatment.
Importantly,
these
medications
also
offer
potential
improvements
towards
advancement
precision
medicine
personalized
population.
However,
remains
great
improve
access
treatment,
increase
menu
approved
treatments,
de-stigmatize
treatment-seeking
Antioxidants,
Journal Year:
2022,
Volume and Issue:
11(7), P. 1374 - 1374
Published: July 15, 2022
Alcohol
use
disorder
(AUD)
is
a
highly
prevalent,
comorbid,
and
disabling
disorder.
The
underlying
mechanism
of
ethanol
neurotoxicity
the
involvement
oxidative
stress
still
not
fully
elucidated.
However,
metabolism
has
been
associated
with
increased
through
alcohol
dehydrogenase,
microsomal
oxidation
system,
catalase
metabolic
pathways.
We
searched
PubMed
genome-wide
association
studies
(GWAS)
catalog
databases
to
review
literature
systematically
summarized
findings
focusing
on
AUD
abstinence
in
relation
stress.
In
addition,
we
reviewed
ClinicalTrials.gov
resource
US
National
Library
Medicine
identify
all
ongoing
completed
clinical
trials
that
include
therapeutic
interventions
based
antioxidants.
retrieved
preclinical
show
impacts
genetics,
metabolism,
inflammation,
neurodegeneration.
American Journal of Psychiatry,
Journal Year:
2025,
Volume and Issue:
182(2), P. 187 - 197
Published: Feb. 1, 2025
The
allostasis
theory
states
that,
as
addiction
develops,
alcohol
is
consumed
to
relieve
negative
affect
rather
than
produce
positive
effects.
This
study
aimed
investigate
the
real-time
subjective
effects
of
in
individuals
with
use
disorder
(AUD)
and
those
prone
by
virtue
having
comorbid
depressive
(DEP).
Participants
(N=221)
completed
high-resolution
ecological
momentary
assessments
during
3-hour
monitoring
one
drinking
episode
non-alcohol
their
natural
environment.
also
daily
mood
surveys
next-day
surveys.
Linear
mixed-effect
models
were
used
compare
behavior
responses
(stimulation,
sedation,
liking,
wanting,
affect)
among
120
participants
AUD
(AUD+;
depression
[DEP+]:
N=64,
without
[DEP-]:
N=56)
101
(AUD-;
DEP+:
N=45,
DEP-:
N=56).
During
period,
an
average
8.5
standard
drinks
(estimated
blood
concentration
[eBAC]=0.115
g/dl)
versus
3.7
(eBAC=0.040
for
non-AUD
participants.
group,
regardless
DEP,
reported
increases
stimulation
rewarding
that
persisted
throughout
most
relative
episode.
To
a
lesser
extent,
relieved
but
this
was
not
specific
or
DEP
groups.
Contrary
model
addiction's
emphasis
on
reinforcement
drinking,
findings
demonstrated
people
displayed
pronounced
prolonged
sensitivity
alcohol's
pleasurable
effects,
akin
noncomorbid
counterparts.
provided
critical
testing
theories
environment
enhance
external
validity.
Addiction,
Journal Year:
2021,
Volume and Issue:
117(6), P. 1543 - 1572
Published: Nov. 3, 2021
Research
has
shown
that
alcohol
use
and
common
mental
disorders
(CMDs)
co-occur;
however,
little
is
known
about
how
the
global
prevalence
of
compares
across
different
CMDs.
We
aimed
to
(i)
report
associations
(alcohol
disorder
(AUD),
binge
drinking
consumption)
comparing
those
with
without
a
CMD,
(ii)
examine
this
differed
among
specific
types
CMDs
(iii)
results
may
differ
by
study
characteristics.We
used
systematic
review
meta-analysis.
Cross-sectional,
cohort,
prospective,
longitudinal
case-control
studies
reporting
CMD
in
general
population
were
identified
using
PsycINFO,
MEDLINE,
PsyARTICLES,
PubMed,
Scopus
Web
Science
until
March
2020.
Depression,
anxiety
phobia
included
as
CMD.
Studies
if
they
standardized
measure
use.
A
random-effects
meta-analysis
was
conducted
generate
pooled
AUD
95%
confidence
intervals
(CI).
narrative
provided
for
consumption
RESULTS:
total
512
full-texts
reviewed,
51
our
final
17
meta-analyses
(n
=
382
201).
Individuals
had
twofold
increase
odds
an
[odds
ratio
(OR)
2.02,
CI
1.72-2.36].
The
having
similar
when
stratified
type
(mood
disorder:
OR
2.00,
1.62-2.47;
anxiety/phobic
1.94,
1.35-2.78).
An
analysis
characteristics
did
not
reveal
any
clear
explanations
between-study
heterogeneity
(I2
>
80%).
There
no
patterns
between
or
consumption,
respectively.People
(depression,
anxiety,
phobia)
are
twice
likely
than
people
disorders.
Journal of Psychopharmacology,
Journal Year:
2021,
Volume and Issue:
35(4), P. 375 - 383
Published: Feb. 18, 2021
3,4-methylenedioxymethamphetamine
(MDMA)
therapy
has
qualities
that
make
it
potentially
well
suited
for
patients
with
addictions,
but
this
never
been
explored
in
a
research
study.
We
present
data
from
the
Bristol
Imperial
MDMA
Alcoholism
(BIMA)
This
is
first
addiction
study,
an
open-label
safety
and
tolerability
proof-of-concept
study
investigating
potential
role
treating
alcohol
use
disorder
(AUD).This
aimed
to
assess
if
MDMA-assisted
psychotherapy
can
be
delivered
safely
tolerated
by
AUD
post
detoxification.
Outcomes
regarding
drinking
behaviour,
quality
of
life
psychosocial
functioning
were
evaluated.Fourteen
completed
community
detoxification
received
eight-week
course
recovery-based
therapy.
Participants
two
sessions
(187.5
mg
each
session).
Psychological
support
was
provided
before,
during
after
session.
Safety
assessed
alongside
psychological
physiological
outcome
measures.
Alcohol
mental
well-being
collected
nine
months
detoxification.MDMA
treatment
all
participants.
No
unexpected
adverse
events
observed.
Psychosocial
improved
across
cohort.
Regarding
use,
at
detox,
average
units
consumption
participants
18.7
per
week
compared
130.6
before
detox.
compares
favourably
previous
observational
(the
'Outcomes'
study)
same
team
similar
population
people
AUD.This
provides
preliminary
novel
intervention
Further
trials
examine
better
therapeutic
approach
are
now
indicated.
JAMA Psychiatry,
Journal Year:
2021,
Volume and Issue:
78(8), P. 922 - 922
Published: June 16, 2021
Treatment
rates
for
alcohol
use
disorder
(AUD)
are
low
1
(eg,
7.6%
in
2019
2
).The
US
Food
and
Drug
Administration
has
approved
4
evidence-based
medications
treating
